Review of NICE Technology Appraisal Guidance No. 221; Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura, and No.293; Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura

The Institute was proposing that TA221; Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura, and TA293; Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura, should be transferred to the ‘static guidance list’.

After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal.

Consequently both TA221 and TA293 will be moved to the ‘static guidance list’. Topics on the static list can be considered for review if any new evidence becomes available that is likely to lead to a change in the existing recommendations.  NICE will also update of the wording of TA221 to clarify that romiplostim and eltrombopag are recommended treatment options for the same patient population and to be consistent with current NICE wording conventions.  This update does not constitute a material change to the existing recommendations for romiplostim.

May 2014

Attachments